CagriSema meta-analysis: what it found

A meta-analysis published August 17, 2026 in Naunyn-Schmiedeberg's Archives of Pharmacology pooled seven randomized controlled trials of cagrisema, Novo Nordisk's investigational combination of cagrilintide and semaglutide^[1], and reported markedly larger weight loss than either drug produced on its own. Across 8,069 participants, the review calculated roughly 7.6 kg more weight loss on cagrisema than on semaglutide alone, 9.2 kg more than on cagrilintide alone, and 14 kg more than on placebo. Cagrisema is not approved anywhere yet, so these numbers describe an investigational combination, not something a clinician can currently prescribe.

What the pooled trials found

The seven trials came from Novo Nordisk's ongoing cagrisema development programme, following participants for up to 68 weeks. The authors ran the review under PRISMA and Cochrane methodology, combined the trial results with random-effects models, graded certainty using the GRADE framework, and scored each trial's risk of bias with the Cochrane RoB 2 tool^[1]. Cagrisema also improved lipid measures compared with placebo, while glycemic results varied more across the pooled trials. The most commonly reported adverse events were gastrointestinal symptoms and injection-site reactions, the same pattern already documented for semaglutide on its own.

The largest trial inside the pool is REDEFINE 1, a 68-week Novo Nordisk trial that randomized 3,417 adults with overweight or obesity to cagrisema, semaglutide alone, cagrilintide alone, or placebo. It reported a mean body-weight reduction of 20.4% on cagrisema at week 68, versus 3.0% on placebo^[2]. That single trial supplies most of the participants, and most of the statistical weight, behind the pooled result.

The precise pooled figures are a mean difference of 7.58 kg more weight loss versus semaglutide alone, 9.24 kg more versus cagrilintide alone, and 13.99 kg more versus placebo, each statistically significant^[1]. Glycemic results were rated heterogeneous across the seven trials, meaning blood-sugar effects varied enough between studies that the authors could not report one clean pooled number the way they could for weight. Lipid improvements over placebo, by contrast, were consistent enough to report directly. The review's own authors reported no competing interests in producing the analysis.

Why pooled trial data is not the same as one big study

A meta-analysis like this one combines the summary results each trial already published. It does not re-analyze the individual patient records behind them. That distinction matters, because trial-level pooling can smooth over real differences between the seven studies: some participants had type 2 diabetes and some did not, doses were tested at different strengths, and follow-up windows did not all reach the same endpoint. The authors addressed part of this by subgrouping results by diabetes status, but a single pooled effect size still averages across trials that were not designed to be identical.

Funding is the second caveat worth keeping in view, and it applies to the trials, not to the review itself. The academic authors who ran this meta-analysis reported no competing interests^[1]. REDEFINE 1 and the other trials they pooled, though, were designed and paid for by Novo Nordisk, the company developing cagrisema for sale^[2]. Industry funding of registration trials is ordinary practice in drug development and does not by itself make the results wrong. A review built almost entirely from one sponsor's own trial programme is still different from an independent, multi-sponsor confirmation. The authors say further large trials are needed to establish how durable the weight loss is and what the longer-term safety profile looks like.

What cagrisema is, and what it is not yet

Cagrisema combines two once-weekly injectable peptides in a single pen: cagrilintide, an amylin-receptor agonist that slows gastric emptying and reduces appetite, and semaglutide, a GLP-1 receptor agonist already approved as Ozempic, Rybelsus and Wegovy. The trials in the pooled review administered cagrilintide 2.4 mg plus semaglutide 2.4 mg once weekly^[2].

Novo Nordisk submitted cagrisema to the FDA in December 2025 for the weight-management indication, and the company has said a decision is expected in the fourth quarter of 2026^[3]. No public filing with the European Medicines Agency has been confirmed. Until a regulator authorizes cagrisema, the medicines a clinician can actually prescribe for weight management remain semaglutide (Wegovy) and tirzepatide (Zepbound), each with its own trial record and label.

What we don't yet know

The pooled analysis stops at 68 weeks, so it cannot say how weight loss on cagrisema behaves after a year or two of continued use, or what happens once someone stops treatment. Meaningful weight regain after discontinuation is already documented in the semaglutide trial record, and nothing in the cagrisema meta-analysis rules out a similar pattern. A head-to-head trial against tirzepatide, the other high-efficacy option already on the market, is also missing from the pool, so where cagrisema ranks against it is still an open question, not a settled one.

Where that leaves someone deciding today

Cagrisema is not something a clinician can prescribe today, in any country. Readers weighing GLP-1 or amylin-based treatment now still have two approved options with a real label and prescribing history: semaglutide and tirzepatide. Whether either fits a given situation is a conversation for a prescribing clinician who knows the person's medical history, not a decision this article can make. The cagrisema numbers above are worth watching. They are not yet a basis for a treatment decision, because the drug does not have an approved label to go with them.